Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$92.37 USD

92.37
11,670,925

-0.97 (-1.04%)

Updated Jun 28, 2024 04:00 PM ET

After-Market: $92.38 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms Guidance

by Zacks Equity Research

Strength in the VITAS and Roto-Rooter branches contributes to Chemed's (CHE) first-quarter top line.

CONMED (CNMD) Beats on Q1 Earnings, Ups '23 EPS View

by Zacks Equity Research

CONMED's (CNMD) adjusted first-quarter sales and earnings recover from the disruption in the fourth quarter due to implementation of a new warehouse management system.

Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Edwards Lifesciences (EW) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Edwards Lifesciences (EW) delivered earnings and revenue surprises of 1.64% and 4.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Philips' (PHG) Q1 Earnings Jump Y/Y on Strong Top-Line Growth

by Zacks Equity Research

Philips' (PHG) first-quarter results benefit from robust performances by the Diagnosis & Treatment and the Connected Care businesses.

Urmimala Biswas headshot

MedTech Stocks' Q1 Earnings on Apr 25: BSX, TMO and More

by Urmimala Biswas

MedTech companies' results are likely to reflect a sequential decline. Let's see how BSX, TMO, EW and ALGN fare this time.

Here's Why You Should Invest in Edwards Lifesciences (EW) Now

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW) on the increased adoption of its premium RESILIA technologies.

The Zacks Analyst Blog Highlights Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI

by Zacks Equity Research

Linde, Vertex Pharmaceuticals, Edwards Lifesciences, General Motors and MSCI are included in this Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Linde, Vertex Pharmaceuticals & Edwards Lifesciences

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Linde plc (LIN), Vertex Pharmaceuticals Incorporated (VRTX) and Edwards Lifesciences Corporation (EW).

What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?

by Zacks Equity Research

Continued demand for the HemoSphere monitoring platform and Smart Recovery is likely to have contributed to the Edwards Lifesciences' (EW) Q1 growth.

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Here's Why You Should Retain Avantor (AVTR) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Avantor's (AVTR) strong product portfolio.

NextGen's (NXGN) New Cloud-Based Solution to Improve Workflow

by Zacks Equity Research

NextGen's (NXGN) latest product is expected to simplify connectivity for healthcare providers, thereby solving clinical data exchange challenges.

HOLX vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

HOLX or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HOLX vs. EW: Which Stock Is the Better Value Option?

Abbott (ABT) Makes Progress in the TAVI Space With Navitor

by Zacks Equity Research

Results from Abbott's (ABT) PORTICO study support Navitor's recent FDA approval to treat patients with severe aortic stenosis who are at high or extreme risk for open-heart surgery.

Abbott's (ABT) MitraClip Device Shows Favorable Outcome

by Zacks Equity Research

Abbott's (ABT) landmark COAPT trial demonstrated that MitraClip is safe and effective and can reduce the hospitalization rate.

Why Is Edwards Lifesciences (EW) Down 2% Since Last Earnings Report?

by Zacks Equity Research

Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Humana (HUM) Exits Business Line to Focus More on Core Units

by Zacks Equity Research

Humana (HUM) will depart from the Employer Group Commercial Medical Products business so that it can invest more funds to grow its core Insurance business lines.

Zacks Industry Outlook Highlights Edwards Lifesciences, IDEXX Laboratories and Hologic

by Zacks Equity Research

Edwards Lifesciences, IDEXX Laboratories and Hologic have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Instruments Stocks to Buy Amid Improving Industry Trends

by Urmimala Biswas

The Zacks Medical - Instruments industry is growing on rising demand for digital health. EW, IDXX and HOLX are set to gain the most. Yet, the ongoing inflation, in the form of rising freight, raw material costs, is disrupting the trend.

Edwards Lifesciences (EW) Gains on Innovation, Margin Growth

by Zacks Equity Research

In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.

SONVY or EW: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SONVY vs. EW: Which Stock Is the Better Value Option?

Select Medical (SEM) Enters JV to Boost New Jersey Healthcare

by Zacks Equity Research

Select Medical (SEM) collaborates with AtlantiCare to open an inpatient rehabilitation hospital and jointly manage the operations of SEM's outpatient centers across New Jersey.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.